Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Metric	ABBVAbbVie	AMGNAmgen	GILDGilead Sciences
Snapshot
Price	$230.01	$344.72	$124.87
Market cap	$382.49B	$182.21B	$153.66B
Valuation
P/E	104.4x	23.5x	16.6x
Forward P/E	120.6x	17.9x	11.8x
Growth
Revenue growth	9.5%	9.1%	3.5%
EPS growth	-13.5%	31.3%	55.5%
Profitability
Net margin	5.8%	21.0%	31.0%
ROE	95.6%	89.4%	42.2%
Balance sheet & cash
Debt / equity	20.19x	6.31x	1.1x
Free cash flow yield	3.9%	6.0%	5.2%
Dividend yield	3.1%	2.9%	2.6%
Verdict
Investment rating	Weak· 31	Favorable· 68	Strong· 74

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

Year	ABBVtoday $230	AMGNtoday $345	GILDtoday $125
2027	$175.96 – $258.07+12% CAGR	$339.39 – $497.77+44% CAGR	$145.62 – $213.58+71% CAGR
2028	$179.48 – $263.23+7% CAGR	$445.51 – $653.42+38% CAGR	$226.42 – $332.09+63% CAGR
2029	$183.07 – $268.50+5% CAGR	$584.82 – $857.74+36% CAGR	$352.07 – $516.37+61% CAGR
2030	$186.73 – $273.87+4% CAGR	$767.70 – $1,125.96+34% CAGR	$547.43 – $802.90+59% CAGR
2031	$190.46 – $279.34+4% CAGR	$1,007.76 – $1,478.04+34% CAGR	$851.20 – $1,248.43+58% CAGR
5-yr CAGR	-3.7% – 4.0%	23.9% – 33.8%	46.8% – 58.5%